Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $84.9B | $90.0B | $92.1B | $104B | $122B | $139B | $157B | $171B | $177B | $199B |
| Revenue growth | — | 6.1% | 2.3% | 13.1% | 16.9% | 13.8% | 13.0% | 9.4% | 3.3% | 12.5% |
| Operating income | $4.80B | $4.17B | $5.43B | $6.00B | $6.36B | $7.56B | $8.28B | $8.50B | $7.86B | $7.20B |
| Operating margin | 5.7% | 4.6% | 5.9% | 5.8% | 5.2% | 5.5% | 5.3% | 5.0% | 4.4% | 3.6% |
| Net income | $2.47B | $3.84B | $3.75B | $4.81B | $4.57B | $6.16B | $5.89B | $5.99B | $5.98B | $5.66B |
| Net margin | 2.9% | 4.3% | 4.1% | 4.6% | 3.8% | 4.4% | 3.8% | 3.5% | 3.4% | 2.8% |
| EPS (diluted) | $9.21 | $14.35 | $14.19 | $18.47 | $17.98 | $24.95 | $24.28 | $25.22 | $25.68 | $25.21 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.27B | $4.18B | $3.83B | $6.06B | $10.7B | $8.36B | $8.40B | $8.06B | $5.81B | $4.29B |
| Capital expenditures | $584M | $791M | $1.21B | $1.08B | $1.02B | $1.09B | $1.15B | $1.30B | $1.26B | $1.12B |
| Free cash flow | $2.69B | $3.39B | $2.62B | $4.98B | $9.67B | $7.28B | $7.25B | $6.76B | $4.55B | $3.17B |
| Share buybacks | $0.00 | $2.00B | $1.69B | $1.70B | $2.70B | $1.90B | $2.32B | $2.68B | $2.90B | $2.60B |
| Dividends paid | $684M | $705M | $776M | $818M | $954M | $1.10B | $1.23B | $1.40B | $1.51B | $1.53B |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.08B | $3.61B | $3.93B | $4.94B | $5.74B | $4.88B | $7.39B | $6.53B | $8.29B | $9.49B |
| Total assets | $65.1B | $70.5B | $71.6B | $77.5B | $86.6B | $97.5B | $103B | $109B | $117B | $121B |
| Total liabilities | $40.0B | $44.0B | $43.0B | $45.7B | $53.4B | $61.3B | $66.4B | $69.5B | $75.5B | $77.5B |
| Long-term debt | $14.4B | $17.4B | $17.2B | $17.8B | $19.3B | $21.2B | $22.3B | $23.2B | $29.2B | $30.8B |
| Shareholders' equity | $25.1B | $26.5B | $28.5B | $31.7B | $33.2B | $36.1B | $36.2B | $39.3B | $41.3B | $43.9B |
| Retained earnings | $16.6B | $18.1B | $20.0B | $22.6B | $23.8B | $27.1B | $29.6B | $31.7B | $33.5B | $35.4B |
| Shares (wtd avg diluted) | 268M | 268M | 264M | 260M | 254M | 247M | 243M | 237M | 233M | 225M |
Every figure is extracted from Elevance Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.